| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Alexei Kharitonenkov | |
| P433 | issue | 6 | |
| P304 | page(s) | 805-810 | |
| P577 | publication date | 2009-08-14 | |
| P1433 | published in | Current Opinion in Pharmacology | Q3007702 |
| P1476 | title | FGFs and metabolism | |
| P478 | volume | 9 |
| Q35981284 | A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis |
| Q38706084 | Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy |
| Q34806589 | Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease |
| Q41842372 | Autofluorescence imaging of living pancreatic islets reveals fibroblast growth factor-21 (FGF21)-induced metabolism. |
| Q35919570 | Bile Acid Metabolome after an Oral Lipid Tolerance Test by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). |
| Q28591360 | C1q/TNF-related protein-12 (CTRP12), a novel adipokine that improves insulin sensitivity and glycemic control in mouse models of obesity and diabetes |
| Q41965207 | CREB3L3 controls fatty acid oxidation and ketogenesis in synergy with PPARα. |
| Q55137606 | CREBH Regulates Systemic Glucose and Lipid Metabolism. |
| Q38977291 | Cardiac actions of fibroblast growth factor 23. |
| Q21135215 | Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study |
| Q36982020 | Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage |
| Q36079923 | Comparing the effects of nano-sized sugarcane fiber with cellulose and psyllium on hepatic cellular signaling in mice |
| Q45222692 | Cynomolgus monkey gallbladder bile contains high concentrations of fibroblast growth factor 19. |
| Q42693830 | DSF Guided Refolding As A Novel Method Of Protein Production |
| Q39374896 | Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. |
| Q51379603 | Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. |
| Q38319578 | Dual actions of fibroblast growth factor 19 on lipid metabolism |
| Q36016804 | Dynamics and Distribution of Klothoβ (KLB) and fibroblast growth factor receptor-1 (FGFR1) in living cells reveal the fibroblast growth factor-21 (FGF21)-induced receptor complex |
| Q63363236 | ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer |
| Q26784095 | Effects of fibroblast growth factor 21 on the heart |
| Q37199307 | Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue |
| Q38809729 | Expression of osteoclastogenic factor transcripts in osteoblast-like UMR-106 cells after exposure to FGF-23 or FGF-23 combined with parathyroid hormone |
| Q49968338 | FGF 21 deficiency slows gastric emptying and reduces initial blood alcohol concentration in mice exposed to acute alcohol in fasting state |
| Q38098144 | FGF, TGFβ and Wnt crosstalk: embryonic to in vitro cartilage development from mesenchymal stem cells |
| Q28741802 | FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways |
| Q40667176 | FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents |
| Q42176870 | FGF21 as an Endocrine Regulator in Lipid Metabolism: From Molecular Evolution to Physiology and Pathophysiology |
| Q28485347 | FGF21 requires βklotho to act in vivo |
| Q26785678 | FGF21, energy expenditure and weight loss - How much brown fat do you need? |
| Q51365036 | FGF23 contributes to insulin sensitivity in obese adolescents - preliminary results. |
| Q35960914 | Fibroblast Growth Factor 21 (FGF-21) in Peritoneal Dialysis Patients: Natural History and Metabolic Implications |
| Q39572533 | Fibroblast Growth Factor 21-Null Mice Do Not Exhibit an Impaired Response to Fasting |
| Q38325739 | Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease |
| Q38058339 | Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. |
| Q50894988 | Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders. |
| Q92980089 | Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma |
| Q35020888 | Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease |
| Q28729024 | Fundamentals of FGF19 & FGF21 action in vitro and in vivo |
| Q37781747 | Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease |
| Q42870834 | Hydrodynamic delivery of FGF21 gene alleviates obesity and fatty liver in mice fed a high-fat diet |
| Q42857128 | Increased FGF21 plasma levels in humans with sepsis and SIRS. |
| Q43589056 | Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity |
| Q24338659 | Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties |
| Q38303572 | Insulin resistance in adolescents with Turner syndrome is comparable to obese peers, but the overall metabolic risk is lower due to unknown mechanism |
| Q38236358 | Klotho: a novel biomarker for cancer |
| Q37538200 | Long-term caloric restriction in ApoE-deficient mice results in neuroprotection via Fgf21-induced AMPK/mTOR pathway |
| Q35833661 | Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes |
| Q38688679 | Potential roles of fibroblast growth factor 21 in the brain |
| Q34685069 | Recently discovered adipokines and cardio-metabolic comorbidities in childhood obesity |
| Q33835303 | Reduced adiposity attenuates FGF21 mediated metabolic improvements in the Siberian hamster. |
| Q55491642 | Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. |
| Q92025196 | Serum FGF21 Levels in Obese Korean Children and Adolescents |
| Q42806569 | Silencing of the Fibroblast growth factor 21 gene is an underlying cause of acinar cell injury in mice lacking MIST1. |
| Q26785313 | Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise |
| Q24306135 | Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho |
| Q34467171 | The Fibroblast Growth Factor signaling pathway |
| Q39197925 | The Potential Role of Fibroblast Growth Factor 21 in Lipid Metabolism and Hypertension |
| Q34568579 | The cooperation of FGF receptor and Klotho is involved in excretory canal development and regulation of metabolic homeostasis in Caenorhabditis elegans. |
| Q34219880 | The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. |
| Q36992839 | The role of Klotho in energy metabolism |
| Q26823032 | The roles of fibroblast growth factors in the testicular development and tumor |
| Q30407643 | Therapeutic utilities of fibroblast growth factor 19. |
| Q34299026 | Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding. |
| Q34572908 | Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved? |
Search more.